Financial Performance - Consolidated revenues for the third quarter ended March 28, 2025, were 211.4million,a1.5208.3 million in the same quarter of the previous year[129]. - The company reported a net loss of 19.2millionforthethirdquarter,comparedtoanetlossof44.6 million in the same quarter last year[129]. - Total revenues rose by 52.2million,or8.9638.9 million for the nine months ended March 28, 2025, compared to 586.7millionintheprioryear[148].−Netlossnarrowedto54.3 million, or 8.5% of revenue, for the nine months ended March 28, 2025, compared to a net loss of 126.9million,or21.619,170,000, resulting in a loss per share of 0.33,comparedtoanetlossof44,574,000 and a loss per share of 0.77forthesameperiodin2024[189].−FortheninemonthsendedMarch28,2025,thenetlosswas54,274,000, with a loss per share of 0.93,comparedtoanetlossof126,863,000 and a loss per share of 2.20forthesameperiodin2024[191].ExpensesandCostManagement−Grossmarginimprovedto27.03.7 million[135]. - Research and development expenses decreased by 25.9% to 16.0 million, primarily due to headcount reductions of 185 R&D employees[138]. - Selling, general and administrative expenses decreased by 0.4% to 43.0 million, attributed to lower bad debt expense and compensation costs[137]. - Total operating expenses were 74.5million,downfrom86.3 million in the prior year, reflecting cost-saving measures[132]. - Selling, general and administrative expenses decreased by 6.7million,or5.4116.7 million during the nine months ended March 28, 2025[153]. - Research and development expenses decreased by 26.2million,or32.055.7 million for the nine months ended March 28, 2025[154]. - Interest expense decreased to 25.4millionduringtheninemonthsendedMarch28,2025,from25.9 million in the same period of 2024[159]. - Other expense, net decreased to 2.9millionduringtheninemonthsendedMarch28,2025,comparedto5.7 million in the prior year[160]. Cash Flow and Liquidity - The company had a net cash inflow of 100.8millionfromoperatingactivitiesfortheninemonthsendedMarch28,2025,comparedtoanoutflowof11.4 million for the same period in 2024[174]. - Cash and cash equivalents increased by 89.3millionfromJune28,2024,toMarch28,2025,totaling269.8 million at the end of the period[173]. - Free cash flow for the third quarter ended March 28, 2025, was 24,060,000,comparedtoanegativefreecashflowof25,743,000 for the same period in 2024[195]. - For the nine months ended March 28, 2025, free cash flow was 85,071,000,whileforthesameperiodin2024,itwasanegative35,322,000[195]. - The company reported net cash provided by operating activities of 29,974,000forthethirdquarterendedMarch28,2025,comparedtoacashusedinoperatingactivitiesof17,805,000 for the same period in 2024[195]. Investments and Strategic Initiatives - The company invested 11.1millionininvestingactivitiesduringtheninemonthsendedMarch28,2025,adecreaseof12.8 million compared to 23.9millioninthesameperiodin2024[175].−Thecompanyisexploringacquisitionsorstrategicalliancesaspartofitsgrowthstrategy[180].EmployeeandWorkforceManagement−Thecompanyhad2,200employeesasofMarch28,2025,focusingonengineeringandresearchtomaintaintechnologicalleads[128].−Restructuringandotherchargesamountedto4.9 million, down from 9.8millionintheprioryear,relatedtoworkforcereductions[140].TaxandRegulatoryMatters−TheeffectivetaxratefortheninemonthsendedMarch28,2025,wasimpactedbyfederalandstateresearchanddevelopmentcreditsandreturntoprovisionadjustments[162].−Thecompanymaintainsavaluationallowanceonthemajorityofforeignnetoperatinglosscarryforwardsandstateresearchanddevelopmenttaxcreditcarryforwards[163].DebtandFinancing−AsofMarch28,2025,thecompanyhadaborrowingcapacityofapproximately900.0 million, with outstanding borrowings of 591.5million[169].−ThecompanyexecutedAmendmentNo.5totheRevolver,increasingtheConsolidatedTotalNetLeverageRatiocovenantfrom4.50to5.25forQ22024[167].LitigationandMarketRisk−Thecompanyexperiencedlitigationandsettlementexpensesof5,467,000 for the third quarter ended March 28, 2025, compared to $2,096,000 for the same period in 2024[189]. - There were no material changes in the company's exposure to market risk from June 28, 2024, to March 28, 2025[199].